logo
Plus   Neg
Share
Email

Novartis: QMF149 Meets Primary Endpoint In Phase III PALLADIUM Trial

Novartis (NVS) announced data from the 52-week Phase III PALLADIUM trial which showed that QMF149, a fixed-dose combination of indacaterol acetate and mometasone furoate, was superior to mometasone furoate at medium and high doses in improving lung function, meeting the primary endpoint. Statistically significant superiority compared to mometasone furoate alone was demonstrated in the key secondary endpoint of improvement in asthma control.

PALLADIUM is part of PLATINUM, the Phase III clinical development program supporting the development of QVM149 and QMF149.

In the study, the overall incidence of adverse events and serious adverse events for indacaterol acetate and mometasone furoate was comparable among treatment groups.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT